Sorry, this entry is only available in Français.
- Würstle
- Lieberknecht-Jouy
- Düchting
- Lößner
- Ceyssens PJ
- pirnay JP
- De Jode
- McCallin S
- Leitner
- Willy
- Leptihn
- Korf
- Idelevich
- Witzenrath
- Faltus
- Ruth
- Blume
- Cornely
- Fickenscher
- Pletz
- Hafkemeyer
- Rohde
- Krut
- Barbirz
- Stahl
- Krüger
- Bugert
- Kempe
- Turner
- Chan
- Ferry T
- Vehreschild
- Classen
- Alt V
- Bend
- gros MF
- Heider
- Hübner
- Kopp
- Maelteni
- Müller
- Nothacker
- Quax
- Rajewski
- Rupp M
- Wittmann
- Ziehr
- Zumpfe
https://doi.org/10.1038/s41591-026-04654-6
Bacteriophages (phages) – viruses that selectively infect bacteria – are a promising option for personalized therapy of difficult-to-treat bacterial infections. Clinical implementation in many countries worldwide, however, faces multiple hurdles, including a lack of consensus on general principles for phage therapy, infrastructural requirements, procedures for quality-assured phage selection and preparation, clinical administration, monitoring and documentation. Existing guidance provides limited practical


